Oramed Pharmaceuticals (NASDAQ:ORMP) Issues Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02, Zacks reports.

Oramed Pharmaceuticals Trading Down 1.5%

ORMP stock traded down $0.05 during midday trading on Friday, reaching $3.27. 47,168 shares of the company’s stock traded hands, compared to its average volume of 208,981. Oramed Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $3.76. The stock has a market cap of $130.15 million, a P/E ratio of 2.59 and a beta of 1.31. The stock’s 50-day moving average is $3.41 and its 200 day moving average is $2.91.

Oramed Pharmaceuticals Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, January 26th. Investors of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s payout ratio is 19.84%.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals presently has an average rating of “Hold”.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE increased its stake in Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after buying an additional 6,261 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 14,297 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 17,510 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 28,406 shares during the period. Finally, Quadrature Capital Ltd bought a new position in shares of Oramed Pharmaceuticals in the fourth quarter worth about $119,000. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.